Newsroom

Download PDF Additional Phase 2 Data Presented at ASCO; Phase 3 TIVO-1 Trial Underway to Evaluate Tivozanib’s Efficacy and Safety Profile CAMBRIDGE, Mass. & CHICAGO, Jun 07, 2010 (BUSINESS WIRE) –AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced data from a subgroup analysis of a

Download PDF Results of Phase 1 Trial Presented at ASCO Annual Meeting CAMBRIDGE, Mass., Jun 05, 2010 (BUSINESS WIRE) –AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has initiated a Phase 2 clinical trial evaluating SCH 900105 (also referred to as AV-299) for

Download PDF CAMBRIDGE, Mass., Jun 02, 2010 (BUSINESS WIRE) –AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the Bank of America Merrill Lynch 2010 Smid Cap Conference on Wednesday, June 9, 2010 at

Download PDF Additional Analyses from Phase 2 Trial of Tivozanib and Phase 1 AV-299 Data to be Presented CAMBRIDGE, Mass., May 20, 2010 (BUSINESS WIRE) –AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that data from the company’s tivozanib and AV-299 (SCH 900105) programs will be

Download PDF Significant Progress in Development of Lead Product Candidate Tivozanib; 2010 Financial Guidance Provided CAMBRIDGE, Mass., Apr 29, 2010 (BUSINESS WIRE) –AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced financial results for the quarter ended March 31, 2010, provided an update on progress towards

Download PDF CAMBRIDGE, Mass., Apr 22, 2010 (BUSINESS WIRE) –AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that financial results for the company’s first quarter ended March 31, 2010 will be released before the market opens on Thursday, April 29, 2010. The management team of

Download PDF Data Presented at AACR 101st Annual Meeting 2010; Confirm Potential Utility of AVEO’s Antibody Pipeline CAMBRIDGE, Mass., Apr 21, 2010 (BUSINESS WIRE) –AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced preclinical data which demonstrate that its Notch1-specific monoclonal antibody is a highly potent inhibitor

Download PDF Milestone Achieved Through Selection of First ErbB3 Antibody Development Candidate CAMBRIDGE, Mass., Apr 14, 2010 (BUSINESS WIRE) –AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced it has received a $5 million milestone payment from Biogen Idec International GmbH, a subsidiary of Biogen Idec, Inc.